Insmed, Inc. (INSM)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow INSM in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on INSM and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
INSM at a glance
Key statistics
$20.89B
Market capitalization
- Previous close
- $95.67
- Open
- $95.00
- Day range
- $94.63 – $97.02
- Volume
- 1.19M
- Average volume (30 sessions)
- 2.68M
- Shares outstanding
- 218.38M
- Earnings per share
- $(4.01)
- Price / book
- 27.6
- Price / sales
- 18.4
- Beta (1 year, vs SPY)
- 0.53
Where the price sits in its year
52-week range
4% of the range
- Below the 52-week high
- -55.3%
- Above the 52-week low
- +5.2%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $105.82-9.6%
- 50-day average
- $117.37-18.5%
- 200-day average
- $128.29-25.4%
In the band below 30 that convention calls oversold. Weak trends can stay there for weeks.
-1.2%
1 week
-20.9%
1 month
-10.3%
3 months
-45.0%
Year to date
-42.3%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with INSM
INSM on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on INSM.
See the plans →
Every planScreen names like INSM
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on INSM
Put INSM on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on INSM
See whether there is an open premium alert on INSM, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
INSM headlines
- Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?
Benzinga · Dec 21, 2025
- Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
Benzinga · Jun 11, 2025
- Insmed Unusual Options Activity For July 11 - Benzinga
Benzinga · Jul 11, 2024
- Where Insmed Stands With Analysts
Benzinga · Nov 20, 2023
- Brady, Airbnb, Insmed And Other Big Stocks Moving Higher On Tuesday
Benzinga · Sep 5, 2023
SEC Form 4, most recent first
Insider filings
Hudson Paul
+6.1K
Director · Grant or award
· Oct 19, 2026
Koppikar Utpal
+6.1K
Director · Grant or award
· Oct 19, 2026
Brennan David R
−25.0K
Director · Open-market sale
$3.10M · Sep 9, 2026
SHAROKY MELVIN MD
−5.0K
Director · Open-market sale
$637.65K · Aug 17, 2026
Adsett Roger
−82.3K
Chief Operating Officer · Option exercise
· Aug 10, 2026
Adsett Roger
+76.6K
Chief Operating Officer · Option exercise
$1.31M · Aug 10, 2026
Adsett Roger
−76.6K
Chief Operating Officer · Option exercise
· Aug 10, 2026
Adsett Roger
−239.8K
Chief Operating Officer · Open-market sale
$31.96M · Aug 10, 2026
About Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Bridgewater, NJ
- Employees
- 1,664
- Listed since
- Jun 1, 2000
- Website
- insmed.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.